Filing Details
- Accession Number:
- 0001628280-23-036757
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-03 16:40:51
- Reporting Period:
- 2023-11-01
- Accepted Time:
- 2023-11-03 16:40:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501697 | X4 Pharmaceuticals Inc | XFOR | Biological Products, (No Disgnostic Substances) (2836) | 273181608 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1880179 | Mary Dibiase | C/O X4 Pharmaceuticals, Inc. 61 North Beacon Street 4Th Floor Boston MA 02134 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-11-01 | 67,695 | $0.73 | 310,844 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023.
- Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6839 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
